83 related articles for article (PubMed ID: 8640549)
1. Pyrazinamide--on the antituberculosis drug frontline.
Mitchison DA
Nat Med; 1996 Jun; 2(6):635-6. PubMed ID: 8640549
[No Abstract] [Full Text] [Related]
2. Pyrazinamide: a frontline drug used for tuberculosis. Molecular mechanism of action resolved after 50 years?
Kalinda AS; Aldrich CC
ChemMedChem; 2012 Apr; 7(4):558-60. PubMed ID: 22241617
[No Abstract] [Full Text] [Related]
3. Correlation of pncA sequence with pyrazinamide resistance level in BACTEC for 21 mycobacterium tuberculosis clinical isolates.
Mestdagh M; Realini L; Fonteyne PA; Rossau R; Jannes G; Mijs W; DE Smet KA; Portaels F; Van den Eeckhout E
Microb Drug Resist; 2000; 6(4):283-7. PubMed ID: 11272256
[TBL] [Abstract][Full Text] [Related]
4. Mutations found in the pncA gene of Mycobacterium tuberculosis in clinical pyrazinamide-resistant isolates from a local region of China.
Zhang H; Bi LJ; Li CY; Sun ZG; Deng JY; Zhang XE
J Int Med Res; 2009; 37(5):1430-5. PubMed ID: 19930847
[TBL] [Abstract][Full Text] [Related]
5. A simplified pyrazinamidase test for pyrazinamide drug susceptibility in Mycobacterium tuberculosis.
Aono A; Chikamatsu K; Yamada H; Igarashi Y; Murase Y; Takaki A; Mitarai S
J Microbiol Methods; 2018 Nov; 154():52-54. PubMed ID: 30316980
[TBL] [Abstract][Full Text] [Related]
6. Escherichia coli genes involved in resistance to pyrazinoic acid, the active component of the tuberculosis drug pyrazinamide.
Schaller A; Guo M; Gisanrin O; Zhang Y
FEMS Microbiol Lett; 2002 Jun; 211(2):265-70. PubMed ID: 12076823
[TBL] [Abstract][Full Text] [Related]
7. Pyrazinamide Resistance among Multidrug-Resistant Mycobacterium tuberculosis Clinical Isolates in Myanmar.
Aung WW; Ei PW; Nyunt WW; Htwe MM; Win SM; Aye KT; Mon AS; Aung ST; Chang CL; Lee JS
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263056
[No Abstract] [Full Text] [Related]
8. pncA Gene Mutations Associated with Pyrazinamide Resistance in Drug-Resistant Tuberculosis, South Africa and Georgia.
Allana S; Shashkina E; Mathema B; Bablishvili N; Tukvadze N; Shah NS; Kempker RR; Blumberg HM; Moodley P; Mlisana K; Brust JC; Gandhi NR
Emerg Infect Dis; 2017 Mar; 23(3):491-495. PubMed ID: 28221108
[TBL] [Abstract][Full Text] [Related]
9. Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis in Brazil.
Rodrigues Vde F; Telles MA; Ribeiro MO; Cafrune PI; Rossetti ML; Zaha A
Antimicrob Agents Chemother; 2005 Jan; 49(1):444-6. PubMed ID: 15616332
[TBL] [Abstract][Full Text] [Related]
10. Mechanistic analysis elucidating the relationship between Lys96 mutation in Mycobacterium tuberculosis pyrazinamidase enzyme and pyrazinamide susceptibility.
Vats C; Dhanjal J; Goyal S; Gupta A; Bharadvaja N; Grover A
BMC Genomics; 2015; 16 Suppl 2(Suppl 2):S14. PubMed ID: 25708048
[No Abstract] [Full Text] [Related]
11. Pyrazinamide.
Tuberculosis (Edinb); 2008 Mar; 88(2):141-4. PubMed ID: 18486055
[No Abstract] [Full Text] [Related]
12. Prevalence and molecular characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates from Southern China.
Pang Y; Zhu D; Zheng H; Shen J; Hu Y; Liu J; Zhao Y
BMC Infect Dis; 2017 Nov; 17(1):711. PubMed ID: 29110640
[TBL] [Abstract][Full Text] [Related]
13. [Determining drug resistance of the clinical strains of Mycobacterium tuberculosis to pyrazinamide].
Nizova AV; Stepanshina VN; Maĭskaia NV; Mironova RI; Bogun AG; Domotenko LV; Morozova TP; Shemiakin IG
Mol Gen Mikrobiol Virusol; 2008; (4):23-6. PubMed ID: 19172875
[TBL] [Abstract][Full Text] [Related]
14. pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis clinical isolates from the southeast region of Brazil.
Barco P; Cardoso RF; Hirata RD; Leite CQ; Pandolfi JR; Sato DN; Shikama ML; de Melo FF; Mamizuka EM; Campanerut PA; Hirata MH
J Antimicrob Chemother; 2006 Nov; 58(5):930-5. PubMed ID: 16971417
[TBL] [Abstract][Full Text] [Related]
15. Comparison of MGIT 960 & pyrazinamidase activity assay for pyrazinamide susceptibility testing of Mycobacterium tuberculosis.
Sharma B; Pal N; Malhotra B; Vyas L; Rishi S
Indian J Med Res; 2010 Jul; 132():72-6. PubMed ID: 20693593
[TBL] [Abstract][Full Text] [Related]
16. pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates in Portugal.
Portugal I; Barreiro L; Moniz-Pereira J; Brum L
Antimicrob Agents Chemother; 2004 Jul; 48(7):2736-8. PubMed ID: 15215139
[TBL] [Abstract][Full Text] [Related]
17. Pyrazinamide Susceptibility and
Rahman A; Ferdous SS; Ahmed S; Rahman SMM; Uddin MKM; Pholwat S; Gratz J; Houpt E; Banu S
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630193
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the BacT/ALERT PZA kit in comparison with the BACTEC 460TB PZA for testing Mycobacterium tuberculosis susceptibility to pyrazinamide.
Aragón LM; Garrigó M; Moreno C; Español M; Coll P
J Antimicrob Chemother; 2007 Sep; 60(3):655-7. PubMed ID: 17615155
[TBL] [Abstract][Full Text] [Related]
19. Simple fibroblast-based assay to test the pyrazinamide susceptibility of Mycobacterium tuberculosis.
Takii T; Hamasaki S; Hirano K; Abe C; Onozaki K
Antimicrob Agents Chemother; 2005 Feb; 49(2):804-7. PubMed ID: 15673774
[TBL] [Abstract][Full Text] [Related]
20. Identification of Novel Efflux Proteins Rv0191, Rv3756c, Rv3008, and Rv1667c Involved in Pyrazinamide Resistance in Mycobacterium tuberculosis.
Zhang Y; Zhang J; Cui P; Zhang Y; Zhang W
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28584158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
